Target to B! - Towards patient-tailored immunotherapy to effectively treat B-cell associated disease
- Conditions
- hematologische aandoeningenB-cell related disordersB-cell mediated immunological or oncological disorders10003816
- Registration Number
- NL-OMON49992
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 2000
1) subjects with a clinical syndrome fulfilling the diagnostic criteria for
pre-specified B-cell-related diseases; 2) disease severity requiring start of
anti-CD20 or antibody targeted therapy and 3) adults or children above the age
of 5 years.
1) anti-CD20 treatment or thymectomy as part of clinical care, within the last
9 months ; 2) plasma exchange, plasmapheresis or immunoadsorption within the
last 3 months ; 3) change in the dose of general immunosuppressive or
oncological drugs, including azathioprine, mycophenolate mofetil, ciclosporin,
tacrolimus within the last 3 months (change in dose of corticosteroids or
intravenous immunoglobulin dose allowed); 4) anti-CD20 treatment or antibody
depleting therapy as part of clinical trials as based on case-based peer review
between researchers
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method